BRAF as a potential therapeutic target in melanoma and other malignancies

被引：146

作者：

Tuveson, DA ^{[1
]}

Weber, BL

Herlyn, M

机构：

[1] Univ Penn, Abramson Family Canc Res Inst, Sch Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Abramson Canc Ctr, Sch Med, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA

[4] Univ Penn, Dept Canc Biol, Sch Med, Philadelphia, PA 19104 USA

[5] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

来源：

CANCER CELL | 2003年 / 4卷 / 02期

关键词：

D O I：

10.1016/S1535-6108(03)00189-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：95 / 98

页数：4

共 29 条

[1]

Brose MS, 2002, CANCER RES, V62, P6997

[2] Mechanisms of regulating the Raf kinase family [J].

Chong, H ;

Vikis, HG ;

Guan, KL .

CELLULAR SIGNALLING, 2003, 15 (05) :463-469

[3] BRAF mutation in papillary thyroid carcinoma [J].

Cohen, J ;

Xing, MZ ;

Mambo, E ;

Guo, ZM ;

Wu, GG ;

Trink, B ;

Beller, U ;

Westra, WH ;

Ladenson, PW ;

Sidransky, D .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627

[4] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[5] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[6] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[7] Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas [J].

Edmunds, SC ;

Cree, IA ;

Dí Nícolantonío, F ;

Hungerford, JL ;

Hurren, JS ;

Kelsell, DP .

BRITISH JOURNAL OF CANCER, 2003, 88 (09) :1403-1405

[8] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[9] BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 [J].

Gorre, ME ;

Ellwood-Yen, K ;

Chiosis, G ;

Rosen, N ;

Sawyers, CL .

BLOOD, 2002, 100 (08) :3041-3044

[10]

Herlyn M, 1996, AM J PATHOL, V149, P739

← 1 2 3 →